Fig. 4

M28z10 T cells showed strong antitumor activity in vivo in an i.p. GC model. a Schematic representation of the experiments. b BLI of BGC-823-GL intraperitoneally injected mice treated with GFP T or M28z10 T cells. NSI mice received an i.p. injection of 1 × 10⁶ BGC-823-GL cells. After 14 days, 5 × 10⁶ M28z10 T cells or the equivalent number of GFP T cells were injected through the tail vein. On days 14, 21, and 33, BLI was conducted. c Statistical analysis of the ROI of each BLI at each time point. Error bars denote the s.e.m., and the results were compared with two-way ANOVA test. *P < 0.05, **P < 0.01, ***P < 0.001. d Percentage of T cells in the PB of BGC-823-GL intraperitoneally injected mice. Error bars denote the s.e.m., and the results were compared with an unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001. e Survival curve of BGC-823-GL intraperitoneally injected mice. The results were performed with Log-rank (Mantel-Cox) test. P value = 0.0014